Annual report pursuant to Section 13 and 15(d)

License Agreements (Details)

v3.20.4
License Agreements (Details) - USD ($)
 1 Months Ended 12 Months Ended
Sep. 30, 2015
May 11, 2015
Jun. 30, 2019
May 31, 2016
Mar. 31, 2015
Dec. 31, 2020
Dec. 31, 2019
Dec. 31, 2016
Neupharma [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees         $ 1,000,000.0      
Neupharma [Member] | Additional Sales Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           $ 40,000,000.0    
Neupharma [Member] | Clinical and Development Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           40,000,000.0    
Neupharma [Member] | Regulatory Approvals To Commercialize The Products [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           22,500,000    
Dana-Farber [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Stock Issued During Period, Shares, Issued for Services 136,830 500,000            
Payment of upfront licensing fees         1,000,000.0      
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners   5.00%            
Cash In Exchange For Common Stock   $ 10,000,000            
Maintenance fee           50,000    
Non-Refundable Milestone Payment           925,000    
Stock Issued During Period, Value, Issued for Services $ 600,000 $ 32,500            
Shares Issued, Price Per Share   $ 0.065            
Dana-Farber [Member] | First Commercial Sale Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           21,500,000    
Dana-Farber [Member] | Additional Sales Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           60,000,000.0    
Maximum potential milestone payments           $ 60,000,000.0    
Jubilant Biosys Ltd [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Payment of upfront licensing fees               $ 2,000,000.0
Revenue recognition milestone revenue recognized             $ 100,000  
Proceeds from upfront fees       $ 1,000,000.0        
Research and development cost           50.00%    
Jubilant Biosys Ltd [Member] | Clinical and Development Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           $ 89,000,000.0    
Jubilant Biosys Ltd [Member] | Regulatory Approvals To Commercialize The Products [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           59,500,000    
Jubilant Biosys Ltd [Member] | Five Regulatory Approvals And First Commercial Sales [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           61,700,000    
Jubilant Biosys Ltd [Member] | Sale Millstone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           89,000,000.0    
Maximum potential milestone payments           89,000,000.0    
Jubilant Biosys Ltd [Member] | Clinical Development and Regulatory Milestones [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           87,200,000    
Adimab LLC [Member] | Clinical and Development Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           7,100,000    
Adimab LLC [Member] | Regulatory Approvals To Commercialize The Products [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           4,800,000    
Collaboration Agreement With TGTX [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone revenue recognized           1,000,000.0 $ 1,600,000  
Proceeds from upfront fees     $ 1,000,000.0   $ 500,000      
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           14,500,000    
Collaboration Agreement With TGTX [Member] | First Commercial Sale Milestone [Member] | PD-L1 [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Maximum potential milestone payments           27,600,000    
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member] | PD-L1 [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           8,400,000    
Collaboration Agreement With TGTX [Member] | Clinical and Development Milestone [Member] | PD-L1 GITR [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           7,000,000.0    
Collaboration Agreement With TGTX [Member] | Commercial Sales In Specified Territories [Member] | PD-L1 [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           19,200,000    
Sublicense Agreement with TGTX [Member] | Clinical and Development Milestone [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           25,500,000    
Collaboration Agreement With GITR [Member] | PD-L1 [Member]                
Research and Development Arrangement, Contract to Perform for Others [Line Items]                
Revenue recognition milestone payments           $ 21,500,000